|> Select your country|
Proof of Harmlessness
An international 3 year clinical study on the daily use of PHYTOSOYA® measured the effects on the endometrium (the internal lining of the uterus) and the breast.
The 305 women taking part in were aged between 45 and 65 years old.
The study consisted of evaluating the daily dosage of 70 mg of isoflavones provided by PHYTOSOYA® for 3 years.
STUDY ON THE ENDOMETRIUM
After 3 years of use, no increase in the thickness of the endometrium was observed.
These results suggest that the specific PHYTOSOYA® extract, providing a daily quantity of 70 mg of isoflavones, does not stimulate the endometrium.
PHYTOSOYA® presents the special characteristic of containing a soya extract rich in daidzein, for which the SAFETY of the endometrium has been clinically proven according to a methodology that concurs with the recommendations of European authorities.
STUDY ON THE BREAST
The results demonstrate that after 3 years of use of PHYTOSOYA®, no change in mammary density was observed.
These results suggest that the specific PHYTOSOYA® extract, providing a daily quantity of 70 mg of isoflavones, does not have any effect on the BREAST.
PHYTOSOYA® presents the special characteristic of containing a soya extract rich in daidzein, the SAFETY of which on the BREAST is clinically proven.
« The studies cited above may not be extrapolated to other soya extracts with different daidzein compositions.
The extract contained in the PHYTOSOYA® range was specifically developed and studied with Laboratoires Arkopharma in order to guarantee its SAFETY. »
|Copyright - Arkopharma Laboratoires Pharmaceutiques
Contact us - Terms and conditions